Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

NCT02993991 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02993991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02993991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Withdrawn
Start date
October 10, 2017
Completion date
December 21, 2017
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable squamous cell carcinoma of oral cavity, squamous cell carcinoma mouth, squamous cell carcinoma, head and neck